Adrenomyeloneuropathy Gene Therapy Trial Begins
The trial will incorporate findings from CYGNET, a natural history study designed to assess the disease progression of AMN.
SwanBio Therapeutics has announced the initiation of the phase 1/2 PROPEL clinical trial (NCT05394064) for SBT101, an investigational gene therapy intended to treat adrenomyeloneuropathy (AMN).1
SBT101 is intended to deliver a functional copy of the human adenosine triphosphate (ATP)-binding cassette transporter subfamily D member 1 gene (hABCD1) via a recombinant adeno-associated virus serotype 9 (AAV9) vector. The multinational, randomized, blinded, dose-escalation PROPEL study will evaluate the safety and efficacy of the therapy for male patients aged 18 to 65 who have been diagnosed with X-linked adrenoleukodystrophy (ALD) with a confirmed mutation in the ABCD1 gene.
The trial will incorporate findings from CYGNET (NCT05008874), a multinational natural history study designed to assess the disease progression of AMN.1,2 CYGNET includes the observation of participants over the course of 2 years and is using wearable technology to track traditional motor tasks, novel activity, and sleep outcomes. The study is also tracking body sway and several other disease severity and functional impairment measures. CYGNET includes male patients aged 18 years and older who have a confirmed diagnosis of ALD and symptoms of AMN with no history of cerebral inflammatory disease and no other major confounding comorbidities. Participants are additionally required to show evidence of spinal cord involvement and to have an Expanded Disability Status Scale score of 1 to 6.5. As of December 13, 2022, the trial had enrolled 65 participants, and is no longer recruiting new patients.
“As we wrap up a pivotal year for SwanBio, I am pleased to announce that we have successfully initiated PROPEL, our first interventional clinical study,” Tom Anderson, chief executive officer and director, SwanBio, said in a statement.1 “This milestone comes on the heels of completing enrollment and over-subscribing our natural history study, CYGNET. These 2 achievements not only demonstrate Swan’s ongoing commitment to the AMN community, but also highlight the exceptional creativity and execution capabilities of our team. We expect to dose the first patient in PROPEL in early 2023 and are well positioned to meet our recruitment goals for this trial.”
The investigational new drug application for SBT101 was originally cleared by the FDA in February of this year.3 The decision was based on the results of preclinical research, data from which was presented in October 2021 at the European Society for Gene and Cell Therapy (ESGCT) Virtual Congress.4 The preclinical research showed dose-dependent expression of hABCD1 and a reduction of VLCFA levels in mouse models.1,4 The therapy was also shown to be well-tolerated in non-human primates through 6 months after treatment. Additional preclinical data was presented at the American Academy of Neurology (AAN) 2022 Annual Meeting in April.5 SBT101 received fast track designation from the FDA in February 2022 and orphan drug designation in March 2022.6,7
